Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. The company develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. It also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Metrics to compare | ZNTL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipZNTLPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.7x | −0.5x | −0.5x | |
PEG Ratio | −0.04 | −0.02 | 0.00 | |
Price/Book | 0.4x | 2.8x | 2.6x | |
Price / LTM Sales | 4.3x | 6.5x | 3.3x | |
Upside (Analyst Target) | 245.9% | 309.8% | 40.3% | |
Fair Value Upside | Unlock | 8.4% | 5.1% | Unlock |